U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314203) titled 'Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer' on Dec. 18, 2025.
Brief Summary: Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy
Study Start Date: Dec. 25, 2026
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer
Surgery
Intervention:
DRUG: Apatinib Mesylate Tablets
Apatinib Mesylate
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Medical University
Information provided by (Responsible Party): ...